{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:58:32Z","timestamp":1779911912325,"version":"3.53.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:00:00Z","timestamp":1735084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006209","name":"Radboud Universitair Medisch Centrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jval.2024.12.005","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T07:36:30Z","timestamp":1735284990000},"page":"224-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction"],"prefix":"10.1016","volume":"28","author":[{"given":"Sanne J.J.P.M.","family":"Metsemakers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella P.M.G.","family":"Hermens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve I.C.G.","family":"Ector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim M.","family":"Govers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jval.2024.12.005_bib1","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jval.2024.12.005_bib2","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"issue":"5405","key":"10.1016\/j.jval.2024.12.005_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A\u00a0new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"suppl 1","key":"10.1016\/j.jval.2024.12.005_bib4","first-page":"S14","article-title":"Current treatment approaches for chronic myelogenous leukemia","volume":"7","author":"Druker","year":"2001","journal-title":"Cancer J (Sudbury, MA)"},{"issue":"1","key":"10.1016\/j.jval.2024.12.005_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jval.2024.12.005_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jval.2024.12.005_bib7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1185\/03007995.2013.812034","article-title":"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib","volume":"29","author":"Goldberg","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.jval.2024.12.005_bib8","first-page":"89","article-title":"Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia","volume":"17","author":"Gu\u00e9rin","year":"2014","journal-title":"J\u00a0Med Econ"},{"issue":"7","key":"10.1016\/j.jval.2024.12.005_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1185\/03007995.2014.904281","article-title":"Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase","volume":"30","author":"Guerin","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.jval.2024.12.005_bib10","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1080\/03007995.2016.1185399","article-title":"Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors: do we know enough?","volume":"32","author":"Breccia","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.jval.2024.12.005_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jnci\/djab185","article-title":"Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: who can benefit the most?","volume":"114","author":"Efficace","year":"2022","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.jval.2024.12.005_bib12","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jval.2024.12.005_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jval.2024.12.005_bib14","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.jval.2024.12.005_bib15","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jval.2024.12.005_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","article-title":"Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing","volume":"32","author":"Medeiros","year":"2018","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.jval.2024.12.005_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11899-019-00524-w","article-title":"Is there a role for dose modification of TKI therapy in CML?","volume":"14","author":"Copland","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"10.1016\/j.jval.2024.12.005_bib18","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.jval.2024.12.005_bib19","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","article-title":"Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation","volume":"3","author":"Yamamoto","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jval.2024.12.005_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"suppl 2","key":"10.1016\/j.jval.2024.12.005_bib23","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s00277-015-2319-x","article-title":"Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU","volume":"94","author":"Conti","year":"2015","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jval.2024.12.005_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.jval.2024.12.005_bib25","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.jval.2024.12.005_bib26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jval.2024.12.005_bib27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0272989X12454577","article-title":"Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20131","volume":"32","author":"Caro","year":"2012","journal-title":"Med Decis Making"},{"issue":"3","key":"10.1016\/j.jval.2024.12.005_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification review and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.12.005_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2009.00663.x","article-title":"Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report\u2014part I","volume":"13","author":"Hay","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2024.12.005_bib30","series-title":"Methodologie van Kostenonderzoek en Referentieprijzen Voor Economische Evaluaties in de Gezondheidszorg in Opdracht van Zorginstituut Nederland Geactualiseerde Versie","first-page":"12","author":"Hakkaart-van Roijen","year":"2015"},{"issue":"1","key":"10.1016\/j.jval.2024.12.005_bib31","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"38","author":"Husereau","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"10.1016\/j.jval.2024.12.005_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2024.12.005_bib33","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/cncr.20694","article-title":"Cost-effectiveness of imatinib versus interferon-\u03b1 plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"101","author":"Reed","year":"2004","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.jval.2024.12.005_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191711110","article-title":"Estimating the burden of stroke: two-year societal costs and generic health-related quality of life of the Restore4Stroke Cohort","volume":"19","author":"van Mastrigt","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"10.1016\/j.jval.2024.12.005_bib35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12471-013-0386-y","article-title":"Treatment costs of acute myocardial infarction in the Netherlands","volume":"21","author":"Soekhlal","year":"2013","journal-title":"Neth Heart J"},{"issue":"2","key":"10.1016\/j.jval.2024.12.005_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jval.2024.12.005_bib37","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.jval.2024.12.005_bib40","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0272989X16686559","article-title":"An overview of R in health decision sciences","volume":"37","author":"Jalal","year":"2017","journal-title":"Med Decis Making"},{"issue":"4","key":"10.1016\/j.jval.2024.12.005_bib41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","article-title":"AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2024.12.005_bib42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3389\/fonc.2020.00883","article-title":"Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia","volume":"10","author":"Annunziata","year":"2020","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.jval.2024.12.005_bib43","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.3390\/cancers13164175","article-title":"Treatment-free remission in chronic myeloid leukemia: can we identify prognostic factors?","volume":"13","author":"Saifullah","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.jval.2024.12.005_bib44","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/bjh.17989","article-title":"The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018","volume":"196","author":"Maas","year":"2022","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.jval.2024.12.005_bib45","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jval.2024.12.005_bib46","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","article-title":"Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modeling study","volume":"6","author":"Shih","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jval.2024.12.005_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5639\/gabij.2019.0802.007","article-title":"Pricing of oral generic cancer medicines in 25 European countries; findings and implications","volume":"8","author":"Godman","year":"2019","journal-title":"GaBI J"},{"issue":"1","key":"10.1016\/j.jval.2024.12.005_bib48","doi-asserted-by":"crossref","DOI":"10.2196\/18901","article-title":"Effect of interactive eHealth interventions on improving medication adherence in adults with long-term medication: systematic review","volume":"23","author":"Pouls","year":"2021","journal-title":"J\u00a0Med Internet Res"},{"issue":"11","key":"10.1016\/j.jval.2024.12.005_bib49","doi-asserted-by":"crossref","first-page":"e854","DOI":"10.1016\/S2352-3026(22)00246-0","article-title":"The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA","volume":"9","author":"Kantarjian","year":"2022","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.jval.2024.12.005_bib51","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","article-title":"Discounting in economic evaluations","volume":"36","author":"Attema","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2024.12.005_bib52","series-title":"Guide to the Methods of Technology Appraisal","author":"Uk","year":"2013"},{"issue":"4","key":"10.1016\/j.jval.2024.12.005_bib53","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1524-4733.2004.74002.x","article-title":"Discounting health outcomes in economic evaluation: the ongoing debate","volume":"7","author":"Severens","year":"2004","journal-title":"Value Health"},{"issue":"19","key":"10.1016\/j.jval.2024.12.005_bib54","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.35384","article-title":"Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase","volume":"130","author":"Haddad","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2024.12.005_bib55","author":"Ehab"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524067962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524067962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T05:12:19Z","timestamp":1740546739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524067962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1098301524067962"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.12.005","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}